Literature DB >> 23660760

Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer.

Sergio Bernardi1, Serena Bertozzi, Ambrogio P Londero, Vito Angione, Roberto Petri, Francesco Giacomuzzi.   

Abstract

INTRODUCTION: Sentinel lymph node biopsy (SLNB) has progressively replaced complete axillary lymph node dissection in the evaluation of breast cancer patients with clinically node-negative disease. Our study investigates the rate of and risk factors involved in sentinel node identification failure.
MATERIALS AND METHODS: We collected data on SLNBs performed during 2002-2010, focusing on tumor, patient, and breast characteristics, radioactivity parameters, and operators' experience. Data were analyzed by R (v2.14.2), considering significance at P values lower than 0.05.
RESULTS: Among 1050 women who underwent an SLNB, the rate of identification failure was 2% (23/1050), which, on bivariate analysis, was seen to be significantly influenced (P<0.05) by the preoperative and intraoperative low radiotracer uptake (axilla/lesion radiotracer uptake ratio<1%), low level of experience of the specialist in nuclear medicine, luminal A subtype, and radiotracer uptake localization in internal mammary lymph nodes. On multivariate analysis, significant risk factors for sentinel node identification failure were found to be: axilla/lesion radiotracer uptake ratio less than 1%, radiotracer uptake localization in internal mammary lymph nodes, and luminal A subtype. Considering only the preoperative variables in our multivariate analysis, axilla/lesion radiotracer uptake ratio less than 1%, negative lymph node scintiscan, and radiotracer uptake localization in internal mammary lymph nodes had an area under the curve (receiver operating characteristic curve) of 96% (95% confidence interval 92-100%). Further, we built a nomogram based on these simple parameters for counseling the patient about the probability of not finding the sentinel lymph node during the surgical procedure.
CONCLUSION: The relatively low prevalence of SLNB failure (2%) is indicative of the accuracy of the procedure when performed by experienced surgeons. The sentinel node identification failure in our population seemed to be related to biological tumor factors (luminal A subtype) and probably to physiological or pathological variations in the lymphatic drainage (axilla/lesion radiotracer uptake ratio<1% and radiotracer uptake localization in internal mammary lymph nodes).

Entities:  

Mesh:

Year:  2013        PMID: 23660760     DOI: 10.1097/MNM.0b013e328361cd84

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.

Authors:  Carla Cedolini; Serena Bertozzi; Ambrogio P Londero; Luca Seriau; Michela Andretta; Diane Agakiza; Sandro Fongione; Alessandro Uzzau; Andrea Risaliti
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Sentinel lymph node mapping using SPECT/CT and gamma probe in endometrial cancer: an analysis of parameters affecting detection rate.

Authors:  Samine Sahbai; Florin-Andrei Taran; Annette Staebler; Diethelm Wallwiener; Christian la Fougère; Sara Brucker; Helmut Dittmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-03       Impact factor: 9.236

3.  Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center.

Authors:  Carla Cedolini; Serena Bertozzi; Luca Seriau; Ambrogio P Londero; Serena Concina; Federico Cattin; Onelio Geatti; Carla Di Loreto; Andrea Risaliti
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

4.  Intraoperative optical coherence tomography for assessing human lymph nodes for metastatic cancer.

Authors:  Ryan M Nolan; Steven G Adie; Marina Marjanovic; Eric J Chaney; Fredrick A South; Guillermo L Monroy; Nathan D Shemonski; Sarah J Erickson-Bhatt; Ryan L Shelton; Andrew J Bower; Douglas G Simpson; Kimberly A Cradock; Z George Liu; Partha S Ray; Stephen A Boppart
Journal:  BMC Cancer       Date:  2016-02-23       Impact factor: 4.430

5.  A novel treatment for metastatic lymph nodes using lymphatic delivery and photothermal therapy.

Authors:  Adewale O Oladipo; Oluwatobi S Oluwafemi; Sandile P Songca; Ariunbuyan Sukhbaatar; Shiro Mori; Junnosuke Okajima; Atsuki Komiya; Shigenao Maruyama; Tetsuya Kodama
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

6.  TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.

Authors:  Serena Bertozzi; Ambrogio P Londero; Luigi Viola; Maria Orsaria; Michela Bulfoni; Stefania Marzinotto; Bruna Corradetti; Umberto Baccarani; Daniela Cesselli; Carla Cedolini; Laura Mariuzzi
Journal:  BMC Cancer       Date:  2021-10-18       Impact factor: 4.430

7.  Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study.

Authors:  Serena Bertozzi; Carla Cedolini; Ambrogio P Londero; Barbara Baita; Francesco Giacomuzzi; Decio Capobianco; Marta Tortelli; Alessandro Uzzau; Laura Mariuzzi; Andrea Risaliti
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.